Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2
The 2',5'- oligoadenylate synthetase (OAS) - ribonuclease L (RNAseL) - phosphodiesterase 12 (PDE12) pathway is an essential interferon-induced effector mechanism against RNA virus infection. Inhibition of PDE12 leads to selective amplification of RNAseL activity in infected cells. We aimed to investigate PDE12 as a potential pan-RNA virus antiviral drug target and develop PDE12 inhibitors that elicit antiviral activity against a range of viruses. A library of 18 000 small molecules was screened for PDE12 inhibitor activity using a fluorescent probe specific for PDE12. The lead compounds (CO-17 or CO-63) were tested in cell-based antiviral assays using encephalomyocarditis virus (EMCV), hepatitis C virus (HCV), dengue virus (DENV), West Nile virus (WNV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in vitro. Cross reactivity of PDE12 inhibitors with other PDEs and in vivo toxicity were measured. In EMCV assays, CO-17 potentiated the effect of IFNα by 3 log10. The compounds were selective for PDE12 when tested against a panel of other PDEs and non-toxic at up to 42 mg kg-1 in rats in vivo. Thus, we have identified PDE12 inhibitors (CO-17 and CO-63), and established the principle that inhibitors of PDE12 have antiviral properties. Early studies suggest these PDE12 inhibitors are well tolerated at the therapeutic range, and reduce viral load in studies of DENV, HCV, WNV and SARS-CoV-2 in human cells and WNV in a mouse model.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:104 |
|---|---|
| Enthalten in: |
The Journal of general virology - 104(2023), 7 vom: 18. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thursz, Mark [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.07.2023 Date Revised 03.04.2024 published: Print ErratumIn: J Gen Virol. 2023 Jul;104(7):. - PMID 37493135 Citation Status MEDLINE |
|---|
| doi: |
10.1099/jgv.0.001865 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359338518 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359338518 | ||
| 003 | DE-627 | ||
| 005 | 20240403234900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1099/jgv.0.001865 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM359338518 | ||
| 035 | |a (NLM)37432877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thursz, Mark |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.07.2023 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: J Gen Virol. 2023 Jul;104(7):. - PMID 37493135 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The 2',5'- oligoadenylate synthetase (OAS) - ribonuclease L (RNAseL) - phosphodiesterase 12 (PDE12) pathway is an essential interferon-induced effector mechanism against RNA virus infection. Inhibition of PDE12 leads to selective amplification of RNAseL activity in infected cells. We aimed to investigate PDE12 as a potential pan-RNA virus antiviral drug target and develop PDE12 inhibitors that elicit antiviral activity against a range of viruses. A library of 18 000 small molecules was screened for PDE12 inhibitor activity using a fluorescent probe specific for PDE12. The lead compounds (CO-17 or CO-63) were tested in cell-based antiviral assays using encephalomyocarditis virus (EMCV), hepatitis C virus (HCV), dengue virus (DENV), West Nile virus (WNV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in vitro. Cross reactivity of PDE12 inhibitors with other PDEs and in vivo toxicity were measured. In EMCV assays, CO-17 potentiated the effect of IFNα by 3 log10. The compounds were selective for PDE12 when tested against a panel of other PDEs and non-toxic at up to 42 mg kg-1 in rats in vivo. Thus, we have identified PDE12 inhibitors (CO-17 and CO-63), and established the principle that inhibitors of PDE12 have antiviral properties. Early studies suggest these PDE12 inhibitors are well tolerated at the therapeutic range, and reduce viral load in studies of DENV, HCV, WNV and SARS-CoV-2 in human cells and WNV in a mouse model | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 2',5'-oligoadenylate synthetase (OAS) | |
| 650 | 4 | |a West Nile virus (WNV) | |
| 650 | 4 | |a dengue virus (DENV) | |
| 650 | 4 | |a hepatitis C virus (HCV) | |
| 650 | 4 | |a ribonuclease L (RNAseL) | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a diethylstilbestrol monophosphate |2 NLM | |
| 650 | 7 | |a 47341-71-9 |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Phosphoric Diester Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.1.4.- |2 NLM | |
| 700 | 1 | |a Sadiq, Fouzia |e verfasserin |4 aut | |
| 700 | 1 | |a Tree, Julia A |e verfasserin |4 aut | |
| 700 | 1 | |a Karayiannis, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Beasley, David W C |e verfasserin |4 aut | |
| 700 | 1 | |a Dejnirattisai, Wanwissa |e verfasserin |4 aut | |
| 700 | 1 | |a Mongkolsapaya, Juthathip |e verfasserin |4 aut | |
| 700 | 1 | |a Screaton, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Wand, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Elmore, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Miles W |e verfasserin |4 aut | |
| 700 | 1 | |a Matthews, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Howard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of general virology |d 1967 |g 104(2023), 7 vom: 18. Juli |w (DE-627)NLM000018821 |x 1465-2099 |7 nnns |
| 773 | 1 | 8 | |g volume:104 |g year:2023 |g number:7 |g day:18 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1099/jgv.0.001865 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 104 |j 2023 |e 7 |b 18 |c 07 | ||